Related Experiment Video
Updated: Feb 7, 2026

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
Published on: May 6, 2015
Novel tumour antigens and the development of optimal vaccine design
Victoria A Brentville1, Suha Atabani1, Katherine Cook1
1Academic Department of Clinical Oncology, University of Nottingham, Nottingham, UK.
Abstract:
The interplay between tumours and the immune system has long been known to involve complex interactions between tumour cells, immune cells and the tumour microenvironment. The progress of checkpoint inhibitors in the clinic in the last decade has highlighted again the role of the immune system in the fight against cancer. Numerous efforts have been undertaken to develop ways of stimulating the cellular immune response to eradicate tumours. These interventions include the identification of appropriate tumour antigens as targets for therapy. In this review, we summarize progress in selection of target tumour antigen. Targeting self antigens has the problem of thymic deletion of high-affinity T-cell responses leaving a diminished repertoire of low-affinity T cells that fail to kill tumour cells. Thymic regulation appears to be less stringent for differentiation of cancer-testis antigens, as many tumour rejection antigens fall into this category. More recently, targeting neo-epitopes or post-translational modifications such as a phosphorylation or stress-induced citrullination has shown great promise in preclinical studies. Of particular interest is that the responses can be mediated by both CD4 and CD8 T cells. Previous vaccines have targeted CD8 T-cell responses but more recently, the central role of CD4 T cells in orchestrating inflammation within tumours and also differentiating into potent killer cells has been recognized. The design of vaccines to induce such immune responses is discussed herein. Liposomally encoded ribonucleic acid (RNA), targeted deoxyribonucleic acid (DNA) or long peptides linked to toll-like receptor (TLR) adjuvants are the most promising new vaccine approaches. These exciting new approaches suggest that the 'Holy Grail' of a simple nontoxic cancer vaccine may be on the horizon. A major hurdle in tumour therapy is also to overcome the suppressive tumour environment. We address current progress in combination therapies and suggest that these are likely to show the most promise for the future.
Insights
Harnessing the immune system to fight cancer is advancing with new strategies for selecting tumor antigens and designing effective cancer vaccines. Novel approaches target neo-epitopes and utilize CD4 T cells, showing promise for simpler, non-toxic therapies.
Area of Science:
- Immunology
- Oncology
- Vaccinology
Background:
- The immune system plays a critical role in cancer surveillance and eradication, as evidenced by the success of checkpoint inhibitors.
- Tumor antigens are key targets for cancer immunotherapy, but challenges exist in eliciting robust anti-tumor immune responses.
- The tumor microenvironment often suppresses immune activity, necessitating strategies to overcome this suppression.
Purpose of the Study:
- To review progress in the selection of tumor antigens for cancer immunotherapy.
- To discuss novel vaccine designs that stimulate cellular immune responses against tumors.
- To explore strategies for overcoming the immunosuppressive tumor microenvironment.
Main Methods:
- Review of current literature on tumor antigen identification and immunotherapy.
- Analysis of emerging vaccine platforms, including RNA, DNA, and peptide-based vaccines.
- Discussion of combination therapies aimed at enhancing anti-tumor immunity.
Main Results:
- Targeting self-antigens is limited by thymic deletion, while cancer-testis antigens are more promising.
- Neo-epitopes and post-translational modifications represent novel targets with significant preclinical promise.
- Both CD4 and CD8 T cells are crucial for anti-tumor immunity, with increasing recognition of CD4 T cell roles.
Conclusions:
- New vaccine approaches, including liposomal RNA, targeted DNA, and peptide-TLR conjugates, offer potential for effective and safe cancer vaccines.
- Overcoming the suppressive tumor microenvironment through combination therapies is essential for future treatment success.
- Advances in antigen selection and vaccine design suggest a promising future for cancer immunotherapy.
More Related Videos
Related Concept Videos
Vaccinations
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Group Design
Optimal Foraging
Factorial Design
Optimization Problems

